Advanced search
1 file | 414.11 KB Add to list

Synthetic biology of modular endolysins

Hans Gerstmans (UGent) , Bjorn Criel (UGent) and Yves Briers (UGent)
(2018) BIOTECHNOLOGY ADVANCES. 36(3). p.624-640
Author
Organization
Abstract
Endolysins and their derivatives have emerged in recent years as a novel class of antibacterials, which have now entered the clinical phases. Their rapid mode-of-action and proteinaceous nature differentiates them from any other class of antibiotics. A key feature of endolysins is their modularity and the opportunities that emerge thereof to customize properties such as specificity, activity, stability and solubility. Extensive protein engineering efforts have expanded the activity spectrum to (pan)drug-resistant Gram-negative bacteria or have improved the activity against Gram-positive pathogens. In addition, specific cell wall binding domains derived from endolysins are exploited for the development of diagnostics.
Keywords
Endolysin, Enzybiotics, Engineering, Mutagenesis, Truncation, Domain swapping, Fusions, clinical trials, RESISTANT STAPHYLOCOCCUS-AUREUS, BACTERIOPHAGE LYTIC ENZYME, WALL BINDING DOMAINS, FATAL PNEUMOCOCCAL PNEUMONIA, RECOMBINANT PHAGE ENDOLYSIN, GRAM-NEGATIVE BACTERIA, ANTIBACTERIAL ACTIVITY, ACINETOBACTER-BAUMANNII, PSEUDOMONAS-AERUGINOSA, ESCHERICHIA-COLI

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 414.11 KB

Citation

Please use this url to cite or link to this publication:

MLA
Gerstmans, Hans, Bjorn Criel, and Yves Briers. “Synthetic Biology of Modular Endolysins.” BIOTECHNOLOGY ADVANCES 36.3 (2018): 624–640. Print.
APA
Gerstmans, H., Criel, B., & Briers, Y. (2018). Synthetic biology of modular endolysins. BIOTECHNOLOGY ADVANCES, 36(3), 624–640.
Chicago author-date
Gerstmans, Hans, Bjorn Criel, and Yves Briers. 2018. “Synthetic Biology of Modular Endolysins.” Biotechnology Advances 36 (3): 624–640.
Chicago author-date (all authors)
Gerstmans, Hans, Bjorn Criel, and Yves Briers. 2018. “Synthetic Biology of Modular Endolysins.” Biotechnology Advances 36 (3): 624–640.
Vancouver
1.
Gerstmans H, Criel B, Briers Y. Synthetic biology of modular endolysins. BIOTECHNOLOGY ADVANCES. 2018;36(3):624–40.
IEEE
[1]
H. Gerstmans, B. Criel, and Y. Briers, “Synthetic biology of modular endolysins,” BIOTECHNOLOGY ADVANCES, vol. 36, no. 3, pp. 624–640, 2018.
@article{8545955,
  abstract     = {Endolysins and their derivatives have emerged in recent years as a novel class of antibacterials, which have now entered the clinical phases. Their rapid mode-of-action and proteinaceous nature differentiates them from any other class of antibiotics. A key feature of endolysins is their modularity and the opportunities that emerge thereof to customize properties such as specificity, activity, stability and solubility. Extensive protein engineering efforts have expanded the activity spectrum to (pan)drug-resistant Gram-negative bacteria or have improved the activity against Gram-positive pathogens. In addition, specific cell wall binding domains derived from endolysins are exploited for the development of diagnostics.},
  author       = {Gerstmans, Hans and Criel, Bjorn and Briers, Yves},
  issn         = {0734-9750},
  journal      = {BIOTECHNOLOGY ADVANCES},
  keywords     = {Endolysin,Enzybiotics,Engineering,Mutagenesis,Truncation,Domain swapping,Fusions,clinical trials,RESISTANT STAPHYLOCOCCUS-AUREUS,BACTERIOPHAGE LYTIC ENZYME,WALL BINDING DOMAINS,FATAL PNEUMOCOCCAL PNEUMONIA,RECOMBINANT PHAGE ENDOLYSIN,GRAM-NEGATIVE BACTERIA,ANTIBACTERIAL ACTIVITY,ACINETOBACTER-BAUMANNII,PSEUDOMONAS-AERUGINOSA,ESCHERICHIA-COLI},
  language     = {eng},
  number       = {3},
  pages        = {624--640},
  title        = {Synthetic biology of modular endolysins},
  url          = {http://dx.doi.org/10.1016/j.biotechadv.2017.12.009},
  volume       = {36},
  year         = {2018},
}

Altmetric
View in Altmetric
Web of Science
Times cited: